AIM ImmunoTech Inc. (AIM) IPO - S-1 Filing, Stock & Insider Activity
AIM ImmunoTech Inc. IPO - Status & S-1 Filing
- Ticker: AIM
- Status: Registered - S-1 filed with the SEC
- S-1 filed: 2025-12-12
- Expected price range: not yet disclosed (set in a later S-1/A or pricing amendment)
- SEC CIK: 0000946644 · View the S-1 on SEC EDGAR →
AIM ImmunoTech Inc. is pre-IPO, so no insider Form 4 transactions have been filed yet. Once insiders begin reporting trades after the offering, they will appear on this page automatically.
Track every registration update on the InsiderAlpha IPO tracker.
Last SEC filing
AIM ImmunoTech Inc. (AIM) - no SEC Form 4 insider filings recorded in the last 90 days. 14 Form 8-K material event filings were reported by AIM in the last 90 days. InsiderAlpha tracks every AIM SEC filing - Form 4, Form 144, and 8-K - in real time, including Rule 10b5-1 plan detection.
About AIM ImmunoTech Inc. (AIM)
AIM ImmunoTech Inc. trades under the ticker AIM. InsiderAlpha tracks 20 primary SEC Form 4 filings from 6 reporting insiders for AIM since 2024, sourced directly from SEC EDGAR.
| Sector | Health Care insider trading |
|---|---|
| SIC classification | Biological Products, (No Diagnostic Substances) (SIC 2836) |
| SEC CIK | 0000946644 |
90-Day SEC Filing Activity
| Form 8-K filings (90d) | 14 |
|---|---|
| Latest Form 4 filing | 2026-03-16 |
Recent AIM Insider Transactions (Form 4)
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Thomas K. Equels | CEO & President | J - Other acquisition / disposition | 25.0K | $0.00 | - | SEC | |
| David I. Chemerow | Director | J - Other acquisition / disposition | 25.0K | $0.00 | - | SEC | |
| David I. Chemerow | Director | A - Grant or award | 2.8K | $1.23 | $3K | SEC | |
| Ted D. Kellner | Director | P - Open-market purchase | 1.97M | $0.03 | $50K | SEC | |
| William M. Mitchell | Director | P - Open-market purchase | 196.9K | $0.03 | $5K | SEC | |
| William M. Mitchell | Director | S - Open-market sale | 4.6K | $0.19 | $884 | SEC | |
| Thomas K. Equels | CEO & President | P - Open-market purchase | 22.7K | $0.21 | $5K | SEC | |
| Stewart Appelrouth | Director | A - Grant or award | 24.5K | $0.21 | $5K | SEC | |
| Nancy Bryan | Director | A - Grant or award | 24.5K | $0.21 | $5K | SEC | |
| William M. Mitchell | Director | A - Grant or award | 24.5K | $0.21 | $5K | SEC | |
| Stewart Appelrouth | Director | A - Grant or award | 22.6K | $0.23 | $5K | SEC | |
| William M. Mitchell | Director | A - Grant or award | 22.6K | $0.23 | $5K | SEC | |
| Stewart Appelrouth | Director | P - Open-market purchase | 1 | $0.21 | $0 | SEC | |
| Stewart Appelrouth | Director | P - Open-market purchase | 11.1K | $0.21 | $2K | SEC | |
| Nancy Bryan | Director | A - Grant or award | 22.6K | $0.23 | $5K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for AIM ImmunoTech Inc. (AIM). Updated in real time as new filings are submitted to the SEC.
Recent AIM Form 8-K Material Events
- - Item 5.07 [SEC]
- - Item 8.01, 9.01 [SEC]
- - Item 1.01, 3.02, 8.01, 9.01 [SEC]
- - Item 5.03, 9.01 [SEC]
- - Other · neutral [SEC]
Trading halt (T1) for AIM. AIM
Recent Insider Filings
- - Thomas K. Equels (CEO & President)
- - David I. Chemerow (Director)
- - Thomas K. Equels (CEO & President)
- - David I. Chemerow (Director)
- - David I. Chemerow (Director)
Form 4 Transaction Code Reference
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in AIM insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
AIM Insider Trading - FAQ
- What is the latest insider trade for AIM?
- AIM ImmunoTech Inc. (AIM) had 0 insider filings in the last 90 days, with the most recent on 2026-03-16. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
- How many insiders are buying AIM stock?
- 0 insider purchases of AIM were filed in the last 90 days.
- How many insiders are selling AIM stock?
- 0 insider sales of AIM were filed in the last 90 days.
- Where can I see AIM SEC filings (Form 4, 10-K, 10-Q, 8-K)?
- This page tracks AIM Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care Companies with Insider Activity
Other companies in the InsiderAlpha index with a significant SEC Form 4 insider-trading footprint:
- $AKTX Akari Therapeutics Plc
- $ALMS ALUMIS INC.
- $ANNX Annexon, Inc.
- $APGE Apogee Therapeutics, Inc.
- $APVO Aptevo Therapeutics Inc.
- $ARTL ARTELO BIOSCIENCES, INC.
- $ARTV Artiva Biotherapeutics, Inc.
- $ASMB ASSEMBLY BIOSCIENCES, INC.
- $ATAI ATAI Life Sciences N.V.
- $AUPH Aurinia Pharmaceuticals Inc.
Related Companies - Recent Insider Activity
- AMGEN INC (AMGN)
- NEUROCRINE BIOSCIENCES INC (NBIX)
- Twist Bioscience Corp (TWST)
- Kymera Therapeutics, Inc. (KYMR)
- EXELIXIS, INC. (EXEL)
- Moderna, Inc. (MRNA)
- RECURSION PHARMACEUTICALS, INC. (RXRX)
- BioCardia, Inc. (BCDA)
- Maze Therapeutics, Inc. (MAZE)
- MeiraGTx Holdings plc (MGTX)
Learn More
- What is SEC Form 4?
- How to read insider buying signals
- Rule 10b5-1 trading plans explained
- The cluster buying signal
Open the live AIM dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.